Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

PresbyLASIK-Isovision bilateral treatment

Search Title by author or title

Session Details

Session Title: Corneal, Scleral and Pharmaceutical Treatment of Presbyopia

Session Date/Time: Monday 09/10/2017 | 16:30-18:00

Paper Time: 16:36

Venue: Meeting Center Room I

First Author: : M.Rau GERMANY

Co Author(s): :    F. Hehn                    

Abstract Details

Purpose:

To evaluate a new Presbylasek approach, correcting distance vision in both eyes equal to emmetropia with an additional treatment of presbyopia with a controlled amount of Q asphericity factor

Setting:

Refractive centre Prague ,CZ ,Centre de la vision 54500 Vandoeuvre, France

Methods:

65 patients with 130 eyes were included . Isovision-technology software was used based on refraction, addition for near, K reading and Q asphericity .It is a two steps treatment in a single procedure . WFO (wavefront optimized treatment) to achieve the emetropia, the second one is an F-CAT ( Q Factor customized ablation treatment) for near vision. We examined the UCVA for distance and near , cornea topography K reading and Q asphericity,emetropia, and F-CAT ( Q Factor customized ablation treatment) for near vision. . The follow up was 1, 3, 6 months.

Results:

Three months postop. 80% of patients achieved binocular UCDVA 16/20 or better and 85% binocular UCNVA p3 or better. 85% of patients were able to read without glasses after one and three months after the surgery. 20 % of patients have a decrease of UCVA for distance after 1 month in average of two lines, after 3 months of 1.75 lines, after 6 months of 0,89 line , 84% of patients were able to read without glasses after one and three months after the surgery. Only 6 % of patients needed glasses for small print occasionally after 6 months.

Conclusions:

The ISOVISION Presbylasik is an effective, safe method in the treatment of presbyopia, without altering the stereovision. Further studies are necessary to confirm these preliminary results

Financial Disclosure:

NONE

Back to previous